| scholarly article | Q13442814 |
| P50 | author | Siow-Ming Lee | Q57200973 |
| Penella Woll | Q57474508 | ||
| P2093 | author name string | David Ferry | |
| Allan Hackshaw | |||
| Mary O'Brien | |||
| Gary Middleton | |||
| Robin Rudd | |||
| Stephen Spiro | |||
| Mark Jitlal | |||
| Kulsam Ali | |||
| Lindsay James | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| angiogenesis inhibitor | Q574834 | ||
| chemotherapy | Q974135 | ||
| thalidomide | Q203174 | ||
| placebo | Q269829 | ||
| P304 | page(s) | 1049-1057 | |
| P577 | publication date | 2009-07-16 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. | |
| P478 | volume | 101 |
| Q92536406 | A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer |
| Q37588040 | Advances in antiangiogenic treatment of small-cell lung cancer |
| Q38254295 | Advances in pharmacotherapy of small cell lung cancer |
| Q35832330 | Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide |
| Q30235046 | Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials |
| Q51150988 | Application of methods for central statistical monitoring in clinical trials. |
| Q36540914 | Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium |
| Q38641871 | Bevacizumab in advanced lung cancer: state of the art. |
| Q35569379 | Chemotherapy for small cell lung cancer: a comprehensive review |
| Q100682871 | Combination therapy: Future directions of immunotherapy in small cell lung cancer |
| Q35155464 | Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer |
| Q36207730 | Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer |
| Q64971959 | Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. |
| Q26826915 | Genomic profiling of small-cell lung cancer: the era of targeted therapies |
| Q38183571 | Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials |
| Q35904003 | Immunotherapy treatments for small-cell lung cancer: past, present and future |
| Q91724678 | Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review |
| Q35843061 | Interpreting small treatment differences from quality of life data in cancer trials: an alternative measure of treatment benefit and effect size for the EORTC-QLQ-C30. |
| Q35583915 | Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms |
| Q37987205 | Management of small cell lung cancer: recent developments for optimal care |
| Q38125489 | Medical treatment of small cell lung cancer: state of the art and new development |
| Q53476716 | Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). |
| Q55062496 | No room for statins in the quest for survival benefits in small cell lung cancer. |
| Q37892341 | Novel strategies for the treatment of small-cell lung carcinoma |
| Q37338005 | Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. |
| Q26750670 | Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review |
| Q38679311 | Personalized Therapy of Small Cell Lung Cancer |
| Q50050385 | Phase II study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an EP regimen |
| Q24289045 | Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic study |
| Q51658011 | Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. |
| Q35808418 | Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study |
| Q26783450 | Research Progression of Maintenance Therapy in Small Cell Lung Cancer |
| Q37604301 | Research progress in the treatment of small cell lung cancer |
| Q36811784 | Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? |
| Q26767020 | Small cell lung cancer (SCLC): no treatment advances in recent years |
| Q34250859 | Small cell lung cancer: therapies and targets |
| Q35836257 | Small cell lung cancer: will recent progress lead to improved outcomes? |
| Q36911934 | Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial |
| Q39326977 | Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes |
| Q36299072 | Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies |
| Q26767017 | Targeted drugs in small-cell lung cancer |
| Q43146801 | Targeted therapies: Thalidomide in lung cancer therapy-what have we learned? |
| Q28068385 | Targeting angiogenesis in small cell lung cancer |
| Q43800002 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study |
| Q33799729 | The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature |
| Q37127932 | The development of targeted therapy in small cell lung cancer |
| Q92745654 | The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer |
| Q33723735 | Treatment options for small cell lung cancer - do we have more choice? |
| Q37728779 | Update in lung cancer and mesothelioma 2009. |
| Q64998413 | [The molecular pathogenesis of small cell lung cancer]. |
Search more.